New Awards for DNA Sequencing

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

Jacob Sands, MD

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Tim Cortese

Navigating Second-Line Treatment Options in Urothelial Carcinoma

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Russ Conroy

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Related Content

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

Jacob Sands, MD

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Tim Cortese

Navigating Second-Line Treatment Options in Urothelial Carcinoma

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Russ Conroy

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.